Comparison of the effects of exenatide and insulin glargine on right and left ventricular myocardial deformation as shown by 2D-speckle-tracking echocardiograms.

Akyay OZ, Sahin T, Cakmak Y, Tarkun I, Selek A, Canturk Z, Cetinarslan B, Karakaya D

Nigerian journal of clinical practice1 Jul 2022Cited by 1 (Europe PMC)

PMID35859471DOI10.4103/njcp.njcp_1640_21PepBankPUB-35859471

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with T2D, 2D-STE parameters did not differ between exenatide and insulin before or after treatment.
In plain wordsHeart strain parameters did not differ between exenatide and insulin before or after treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant change2D-STE treatment comparison
Study
n = 27
Comparator
Insulin glargine
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · six monthsAs given in this study (human).
Source sentences
Summary
Based on 2D-STE parameters the two treatments did not differ statistically in either pre- or post-treatment periods.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, 27 patients with type 2 diabetes were randomized into exenatide and insulin glargine treatment groups.
Summary · context
The patients were monitored for six months by conventional echocardiography (ECHO) and 2D-speckle-tracking echocardiography (2D-STE) to evaluate right and left ventricular functions.
Report a problemFND-3585947108
02HumanRandomized controlled trialEfficacy outcome
In patients with T2D, A4C-based left ventricular strain improved from baseline with exenatide.
In plain wordsExenatide improved one view-based measure of left heart strain compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedA4C left ventricular strain
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · six monthsAs given in this study (human).
Source sentences
Summary
In the exenatide group, LVGLS based on A4C values improved (p: 0.048), while ALA, A2C, and LVGLS values did not change.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, 27 patients with type 2 diabetes were randomized into exenatide and insulin glargine treatment groups.
Summary · context
The patients were monitored for six months by conventional echocardiography (ECHO) and 2D-speckle-tracking echocardiography (2D-STE) to evaluate right and left ventricular functions.
Report a problemFND-3585947103
03HumanRandomized controlled trialEfficacy outcome
In patients with T2D, ALA-based left ventricular strain did not change with exenatide.
In plain wordsOne long-axis measure of left heart strain did not change during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeALA left ventricular strain
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · six monthsAs given in this study (human).
Source sentences
Summary
In the exenatide group, LVGLS based on A4C values improved (p: 0.048), while ALA, A2C, and LVGLS values did not change.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, 27 patients with type 2 diabetes were randomized into exenatide and insulin glargine treatment groups.
Summary · context
The patients were monitored for six months by conventional echocardiography (ECHO) and 2D-speckle-tracking echocardiography (2D-STE) to evaluate right and left ventricular functions.
Report a problemFND-3585947104
04HumanRandomized controlled trialEfficacy outcome
In patients with T2D, A2C-based left ventricular strain did not change with exenatide.
In plain wordsOne two-chamber measure of left heart strain did not change during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeA2C left ventricular strain
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · six monthsAs given in this study (human).
Source sentences
Summary
In the exenatide group, LVGLS based on A4C values improved (p: 0.048), while ALA, A2C, and LVGLS values did not change.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, 27 patients with type 2 diabetes were randomized into exenatide and insulin glargine treatment groups.
Summary · context
The patients were monitored for six months by conventional echocardiography (ECHO) and 2D-speckle-tracking echocardiography (2D-STE) to evaluate right and left ventricular functions.
Report a problemFND-3585947105
05HumanRandomized controlled trialEfficacy outcome
In patients with T2D, overall left ventricular global longitudinal strain did not change with exenatide.
In plain wordsOverall left heart strain did not change during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeLeft ventricular global longitudinal strain
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · six monthsAs given in this study (human).
Source sentences
Summary
In the exenatide group, LVGLS based on A4C values improved (p: 0.048), while ALA, A2C, and LVGLS values did not change.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, 27 patients with type 2 diabetes were randomized into exenatide and insulin glargine treatment groups.
Summary · context
The patients were monitored for six months by conventional echocardiography (ECHO) and 2D-speckle-tracking echocardiography (2D-STE) to evaluate right and left ventricular functions.
Report a problemFND-3585947106
06HumanRandomized controlled trialEfficacy outcome
In patients with T2D, right ventricular global longitudinal strain improved after exenatide treatment.
In plain wordsRight heart strain improved from baseline during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedRight ventricular global longitudinal strain
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · six monthsAs given in this study (human).
Source sentences
Summary
Moreover, the RVGLS values improved significantly after exenatide treatment (p: 0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, 27 patients with type 2 diabetes were randomized into exenatide and insulin glargine treatment groups.
Summary · context
The patients were monitored for six months by conventional echocardiography (ECHO) and 2D-speckle-tracking echocardiography (2D-STE) to evaluate right and left ventricular functions.
Report a problemFND-3585947107

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

07HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with T2D, conventional echocardiographic parameters other than TAPSE did not change in either treatment group.
In plain wordsHeart ultrasound measures other than TAPSE did not change in either treatment group.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeConventional echocardiography
Study
n = 27
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
ECHO parameters did not change significantly pre- and post-treatment, except for the tricuspid annular plane systolic excursion (TAPSE) values.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, 27 patients with type 2 diabetes were randomized into exenatide and insulin glargine treatment groups.
Summary · context
The patients were monitored for six months by conventional echocardiography (ECHO) and 2D-speckle-tracking echocardiography (2D-STE) to evaluate right and left ventricular functions.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3585947101
08HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with T2D, TAPSE increased from baseline in both exenatide and insulin groups.
In plain wordsTAPSE increased in both groups, including the insulin group.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseTAPSE
Study
n = 27
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
Post-treatment TAPSE values significantly increased in both groups compared to pre-treatment values.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, 27 patients with type 2 diabetes were randomized into exenatide and insulin glargine treatment groups.
Summary · context
The patients were monitored for six months by conventional echocardiography (ECHO) and 2D-speckle-tracking echocardiography (2D-STE) to evaluate right and left ventricular functions.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3585947102

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.